Daclatasvir CAS 1009119-64-5 Powder Raw Materials

CAS: 1009119-64-5

MF: C40H50N8O6

MW: 738.88

EINECS: 1592732-453-0

Specification​: 99% min Daclatasvir

Sample: Daclatasvir Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Daclatasvir Powder Usage and Synthesis.

Daclatasvir Powder (Daklinza) has been granted Priority Review status in combination with Sofosbuvir for the treatment of adult patients with genotype 3 chronic hepatitis C. Daclatasvir CAS 1009119-64-5 is the first drug to demonstrate safe efficacy in the treatment of genotype 3 hepatitis C virus infection without the need for coadministration with interferon or ribavirin. 

Daclatasvir is the first drug to demonstrate safe and effective treatment of genotype 3 hepatitis C virus infection without co-administration with interferon or ribavirin, and Daclatasvir Raw Materials Raw Materials has demonstrated potent antiviral effects across genotypes 1-6 hepatitis C viruses. The current mainstream regimen for daclatasvir is the daclatasvir + sofosbuvir combination. 

Daclatasvir Powder is characterised by good efficacy, higher SVR, fewer side effects and shorter treatment cycles than other regimens.

Uses and functions of Daclatasvir Powder.

Dacatavir is a hepatitis C virus (HCV) NS5A inhibitor that is indicated for the treatment of chronic hepatitis C infection with genotype 3 infection. On July 24, 2015, the FDA approved Squibb's chronic hepatitis C drug Daclatasvir-dactamivir for marketing. Squibb's application for FDA approval of dactamivir was also tortuously rejected by the FDA, but was finally approved in mid-2015, and the FDA approved the combination of dactamivir and sofibuvir for the treatment of hepatitis C genotype 3 patients.

Daclatasvir (BMS-790052) is a highly selective HCV NS5A inhibitor with an EC50 of 9-50 pM that acts in cell culture on infectious viruses of multiple HCV replication genotypes and JFH-1 genotype 2a. Phase 3.BMS-790052 is a first-in-class, highly selective NS5A inhibitor of hepatitis C virus (HCV) with an EC50 of picomolarity.

Pharmacological Effects of Daclatasvir Powder.

Daclatasvir Powder is an HCV NS5A protein inhibitor NS5A protein is a multifunctional protein critical for viral replication. It inhibits the replication of HCV RNA and the assembly of viral particles.It should not be used alone, but in combination with sofosbuvir or pegylated interferon and ribavirin.

Production method of Daclatasvir Powder.